FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 842 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with... January 22, 2024 How Pelvic Floor Therapy Can Help People With Prostate Cancer and... December 13, 2022 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab April 28, 2021 Rate of Suicides Related to Cancer Is Declining February 17, 2021 Load more HOT NEWS Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with... Working Outdoors in the Sunshine May Lower Your Risk of Breast... FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head...
